D. Anonymous, Dengue Haemorrhagic Fever and Dengue Shock Syndrome in the Context of the Integrated Management of Childhood Illness, World Health Organization, p.13, 2005.

S. Whitehead, J. Blaney, A. Durbin, and M. Br, Prospects for a dengue virus vaccine, Nature Reviews Microbiology, vol.193, issue.7, pp.518-528, 2007.
DOI : 10.1038/nrmicro1690

S. Weaver and N. Vasilakis, Molecular evolution of dengue viruses: Contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease, Infection, Genetics and Evolution, vol.9, issue.4, pp.523-563, 2009.
DOI : 10.1016/j.meegid.2009.02.003

N. Massé, B. Selisko, and H. Malet, Le virus de la dengue : cibles virales et antiviraux, Virologie, vol.11, issue.2, pp.121-133, 2007.

P. Gurugama, P. Garg, J. Perera, A. Wijewickrama, and S. Seneviratne, Dengue viral infections, Indian J Dermatol, vol.55, pp.68-78, 2010.

D. Bente, R. , and R. , Models of dengue virus infection, Drug Discovery Today: Disease Models, vol.3, issue.1, pp.97-103, 2006.
DOI : 10.1016/j.ddmod.2006.03.014

N. Arunachalam, S. Tana, and F. Espino, Eco-bio-social determinants of dengue vector breeding: a multicountry study in urban and periurban Asia, Bulletin of the World Health Organization, vol.88, issue.3, pp.173-184, 2010.
DOI : 10.2471/BLT.09.067892

. Anonymous, Surveillance du moustique exotique Aedes albopictus en France métropolitaine, ville d'Hyères (Var) http://www.villehyeres .fr/visiteur, 2010.

. Anonymous, Dengue haemorrhagic fever: diagnosis, treatment, prevention and control : World Health Organization, 1997.

S. Bandyopadhyay, L. Lum, and A. Kroeger, Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever, Tropical Medicine and International Health, vol.28, issue.8, pp.1238-55, 2006.
DOI : 10.1016/0035-9203(94)90225-9

C. Phuong, N. Nhan, and R. Kneen, Clinical Diagnosis and assessment of severity of confirmed dengue infections in Vietnamese Children: Is the World Health Organization Classification system helpful, Am J Trop Med Hyg, vol.70, issue.2, pp.172-181, 2004.

P. Gupta, V. Khare, and S. Tripathi, Assessment of World Health Organization definition of dengue hemorrhagic fever in North India, The Journal of Infection in Developing Countries, vol.4, issue.03, pp.150-155, 2010.
DOI : 10.3855/jidc.708

J. Deen, E. Harris, and B. Wills, The WHO dengue classification and case definitions: time for a reassessment, The Lancet, vol.368, issue.9530, pp.368170-173, 2006.
DOI : 10.1016/S0140-6736(06)69006-5

J. Rigau-perez, Severe dengue: the need for new case definitions, The Lancet Infectious Diseases, vol.6, issue.5, pp.297-302, 2006.
DOI : 10.1016/S1473-3099(06)70465-0

S. Bandyopadhyay, L. Lum, and A. Kroeger, Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Tropical Medicine and International Health, pp.111238-1255, 2006.

D. Guha-sapir and B. Schimmer, Dengue fever: new paradigms for a changing epidemiology, Emerging Themes in Epidemiology, vol.2, issue.1, p.1, 2005.
DOI : 10.1186/1742-7622-2-1

S. Hay, M. Myers, and D. Burke, Etiology of interepidemic periods of mosquito-borne disease, Proceedings of the National Academy of Sciences, vol.97, issue.16, pp.979335-979344, 2000.
DOI : 10.1073/pnas.97.16.9335

J. Toussaint, P. Kerkhofs, and K. De-clercq, Influence des changements climatiques globaux sur la progression des arboriroses, Ann. Méd. Vét, vol.150, pp.56-63, 2006.

A. Kl, N. Nguyet, and N. Chau, Epidemiological Factors Associated with Dengue Shock Syndrome and Mortality in Hospitalized Dengue Patients in Ho Chi Minh City, Vietnam. Am, J. Trop. Med. Hyg, vol.84, issue.1, pp.127-134, 2001.

B. Lambdin, M. Schmaedick, and S. Mcclintock, Dry Season Production of Filariasis and Dengue Vectors in American Samoa and Comparison with Wet Season Production, American Journal of Tropical Medicine and Hygiene, vol.81, issue.6
DOI : 10.4269/ajtmh.2009.09-0115

H. Thu, K. Lowry, and T. Myint, Myanmar Dengue Outbreak Associated with Displacement of Serotypes 2, 3, and 4 by Dengue 1. Emerg Infect Dis, pp.593-600, 2004.

M. Johansson, D. Cummings, and G. Glass, Multiyear Climate Variability and Dengue? El Nin?o Southern Oscillation, Weather, and Dengue Incidence in Puerto Rico, Mexico, and Thailand: A Longitudinal Data Analysis, PLoS Med, issue.11, pp.6-1000185, 2009.

M. Tipayamongkholgul, C. Fang, S. Klinchan, C. Liu, and C. King, Effects of the El Niñosouthern oscillation on dengue epidemics in Thailand, BMC Public Health, issue.9, p.422, 1996.

W. Tabachnick, Challenges in predicting climate and environmental effects on vector-borne disease episystems in a changing world, Journal of Experimental Biology, vol.213, issue.6, pp.946-54, 2010.
DOI : 10.1242/jeb.037564

Y. Hsieh and C. Chen, Turning points, reproduction number, and impact of climatological events for multi-wave dengue outbreaks, Tropical Medicine & International Health, vol.24, issue.6, pp.628-666, 2009.
DOI : 10.1111/j.1365-3156.2009.02277.x

E. Khan, M. Kisat, N. Khan, A. Nasir, S. Ayub et al., Demographic and Clinical Features of Dengue Fever in Pakistan from 2003???2007: A Retrospective Cross-Sectional Study, PLoS ONE, vol.4, issue.9, 2010.
DOI : 10.1371/journal.pone.0012505.t002

S. Green and A. Et-rothman, Immunopathological mechanisms in dengue and dengue hemorrhagic fever, Current Opinion in Infectious Diseases, vol.19, issue.5, pp.429-436, 2006.
DOI : 10.1097/01.qco.0000244047.31135.fa

S. Halstead, Neutralization and Antibody-Dependent Enhancement of Dengue Viruses, Adv Virus Res, vol.60, pp.421-67, 2003.
DOI : 10.1016/S0065-3527(03)60011-4

D. G. Nielsen, The relationship of interacting immunological components in dengue pathogenesis, Virology Journal, vol.6, issue.1, p.211, 2009.
DOI : 10.1186/1743-422X-6-211

D. Webster, J. Farrar, R. , and S. , Progress towards a dengue vaccine, The Lancet Infectious Diseases, vol.9, issue.11, pp.678-87
DOI : 10.1016/S1473-3099(09)70254-3

M. Beltramello, K. Williams, and C. Simmons, The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity, Cell Host Microbe, pp.271-83, 2010.

W. Dejnirattisai, A. Jumnainsong, and N. Onsirisakul, Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans, Science, pp.328745-328753, 2010.

Y. Yen, H. Chen, Y. Lin, C. Shieh, and B. Wu-hsieh, Enhancement by Tumor Necrosis Factor Alpha of Dengue Virus-Induced Endothelial Cell Production of Reactive Nitrogen and Oxygen Species Is Key to Hemorrhage Development, J virol, issue.24, pp.8212312-12324, 2008.

S. Thein, M. Aung, and T. Shwe, Risk factors in dengue shock syndrome, Am J Trop Med Hyg, vol.56, issue.5, pp.566-572, 1997.

N. Sangkawibha, S. Rojanasuphot, S. Ahandrik, S. Viriyapongse, and S. Jatanasen, RISK FACTORS IN DENGUE SHOCK SYNDROME: A PROSPECTIVE EPIDEMIOLOGIC STUDY IN RAYONG, THAILAND, American Journal of Epidemiology, vol.120, issue.5, pp.653-669, 1984.
DOI : 10.1093/oxfordjournals.aje.a113932

M. Guzmán, G. Kourí, L. Valdés, J. Bravo, S. Vázquez et al., Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks, Revista Panamericana de Salud P??blica, vol.11, issue.4, pp.223-230, 2002.
DOI : 10.1590/S1020-49892002000400003

A. Balmaseda, S. Hammond, L. Pérez, and Y. Tellez, Serotype-specific differences in clinical manifestations of dengue, Am J Trop Med Hyg, issue.3, pp.74449-56, 2006.

A. Nisalak, T. Endy, S. Nimmannitya, and S. Kalayanarooj, Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999, Am J Trop Med Hyg, issue.2, pp.68-191, 2003.

E. Harris, E. Videa, L. Pérez, and E. Sandoval, Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua, Am J Trop Med Hyg, vol.63, issue.1 2, pp.5-11, 2000.

T. Endy, S. Chunsuttiwat, A. Nisalak, and D. Libraty, Epidemiology of Inapparent and Symptomatic Acute Dengue Virus Infection: A Prospective Study of Primary School Children in Kamphaeng Phet, Thailand, American Journal of Epidemiology, vol.156, issue.1, pp.40-51, 2002.
DOI : 10.1093/aje/kwf005

R. Graham, M. Juffrie, R. Tan, and C. Hayes, A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996, Am J Trop Med Hyg, issue.3, pp.61-412, 1999.

J. Fried, R. Gibbons, S. Kalayanarooj, and S. Thomas, Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006, PLoS Neglected Tropical Diseases, vol.329, issue.1, p.617, 1994.
DOI : 10.1371/journal.pntd.0000617.t003

D. Vaughn, S. Green, S. Kalayanarooj, and B. Innis, Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity, The Journal of Infectious Diseases, vol.181, issue.1, pp.2-9, 2000.
DOI : 10.1086/315215

T. Endy, A. Nisalak, and S. Chunsuttiwat, Spatial and Temporal Circulation of Dengue Virus Serotypes: A Prospective Study of Primary School Children in Kamphaeng Phet, Thailand, American Journal of Epidemiology, vol.156, issue.1, pp.52-61, 2002.
DOI : 10.1093/aje/kwf006

R. Rico-hesse, Dengue Virus Evolution and Virulence Models, Clinical Infectious Diseases, vol.44, issue.11, pp.1462-1468, 2007.
DOI : 10.1086/517587

J. Hanna, Dengue diagnostics: recommendations from the Asia-Pacific and the Americas dengue prevention boards. International Vaccine Institute

V. Tricou, Etude comparative de deux tests de détection rapide de la protéine NS1 pour le diagnostic de la dengue, Thèse n°56, 2010.

Q. Wang, S. Patel, and E. Vangrevelinghe, A Small-Molecule Dengue Virus Entry Inhibitor, Antimicrobial Agents and Chemotherapy, vol.53, issue.5, pp.531823-1831, 2009.
DOI : 10.1128/AAC.01148-08

Z. Zhou, M. Khaliq, and J. Suk, Antiviral Compounds Discovered by Virtual Screening of Small???Molecule Libraries against Dengue Virus E Protein, ACS Chemical Biology, vol.3, issue.12, pp.765-775, 2008.
DOI : 10.1021/cb800176t

C. Yang, Y. Hsieh, and S. Lee, Novel Dengue Virus-Specific NS2B/NS3 Protease Inhibitor, BP2109, Discovered by a High-Throughput Screening Assay, Antimicrobial Agents and Chemotherapy, vol.55, issue.1, pp.55229-238, 2011.
DOI : 10.1128/AAC.00855-10

S. Tomlinson and S. Watowich, Anthracene-based inhibitors of dengue virus NS2B???NS3 protease???, Antiviral Research, vol.89, issue.2, pp.127-162, 2011.
DOI : 10.1016/j.antiviral.2010.12.006

S. Tomlinson, R. Malmstrom, A. Russo, N. Mueller, Y. Pang et al., Structure-based discovery of dengue virus protease inhibitors, Antiviral Research, vol.82, issue.3, pp.110-114, 2009.
DOI : 10.1016/j.antiviral.2009.02.190

P. Niyomrattanakit, Y. Chen, and H. Dong, Inhibition of Dengue Virus Polymerase by Blocking of the RNA Tunnel, Journal of Virology, vol.84, issue.11, pp.845678-5686, 2010.
DOI : 10.1128/JVI.02451-09

S. Lim, L. Sonntag, and C. Noble, Small Molecule Inhibitors That Selectively Block Dengue Virus Methyltransferase, Journal of Biological Chemistry, vol.286, issue.8, pp.2866233-2866273, 2010.
DOI : 10.1074/jbc.M110.179184

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057852

B. Innis and K. H. Eckels, Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command, Am J Trop Med Hyg, issue.6, pp.691-695, 2003.

S. Simasathien, T. S. Watanaveeradej, and V. , Safety and Immunogenicity of a Tetravalent Live-attenuated Dengue Vaccine in Flavivirus Naive Children, Am. J. Trop

. Anonymous, Guidelines for the clinical evaluation of dengue vaccines in endemic areas, 2008.

. Anonymous, Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses, p.7

S. Thomas, N. Nisalak, and K. Anderson, Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance, American Journal of Tropical Medicine and Hygiene, vol.81, issue.5, pp.825-833, 2009.
DOI : 10.4269/ajtmh.2009.08-0625

K. H. Eckels, D. D. Putnak, and R. , Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys, Am, J. Trop. Med. Hyg, issue.6, pp.69-81, 2003.

S. Halstead and N. J. Et-marchette, Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii, Am. J. Trop

K. Eckels, W. Brandt, V. Harrison, J. Mccown, and P. Russell, Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development, Infect Immun, issue.5, pp.141221-1227, 1976.

R. Edelman, S. S. Wasserman, and S. Bodison, A, Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine, Am, J. Trop. Med. Hyg, issue.6, pp.69-117, 2003.

W. Sun, R. Edelman, and N. Kanesa-thasan, Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates, Am. J. Trop

W. Sun, D. Cunningham, and S. S. Wasserman, Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-na??ve adults, Human Vaccines, vol.5, issue.1, pp.33-40, 2009.
DOI : 10.4161/hv.5.1.6348

P. Koraka, S. Benton, G. Van-amerongen, K. Stittelaar, and A. Osterhaus, Efficacy of a live attenuated tetravalent candidate dengue vaccine in na??ve and previously infected cynomolgus macaques, Vaccine, vol.25, issue.29, pp.5409-5425, 2007.
DOI : 10.1016/j.vaccine.2007.04.079

V. Gunther, R. Putnak, and K. Eckels, A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness, Vaccine, vol.29, issue.22, pp.293895-904, 2011.
DOI : 10.1016/j.vaccine.2011.03.038

N. Bhamarapravati and S. Yoksan, Live attenuated tetravalent dengue vaccine, Vaccine, vol.18, issue.2, pp.44-51, 2000.
DOI : 10.1016/S0264-410X(00)00040-2

D. Vaughn, C. Hoke, . Jr, and S. Yoksan, Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers, Vaccine, vol.14, issue.4, pp.329-365, 1996.
DOI : 10.1016/0264-410X(95)00167-Y

N. Kanesa-thasan, W. Sun, and G. Kim-ahn, Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers, Vaccine, vol.19, issue.23-24, pp.23-243179, 2001.
DOI : 10.1016/S0264-410X(01)00020-2

A. Sabchareon, J. Lang, and P. Chanthavanich, Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses, Am, J. Trop. Med. Hyg, issue.3, pp.66264-272, 2002.

A. Sabchareon, J. Lang, and P. Chanthavanich, Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children, The Pediatric Infectious Disease Journal, vol.23, issue.2, pp.99-109, 2004.
DOI : 10.1097/01.inf.0000109289.55856.27

S. Kitchener, M. Kitchener, and P. Nasveld, Immunogenicity and safety of two liveattenuated tetravalent dengue vaccine formulations in healthy Australian adults, Vaccine, issue.9, pp.241238-1241, 2006.

A. L. Rothman, N. Kanesa-thasan, K. West, J. J. Saluzzo, J. Ennis et al., Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine, Vaccine, vol.19, issue.32, pp.194694-4699, 2001.
DOI : 10.1016/S0264-410X(01)00236-5

P. Chanthavanich, C. Lunxembruger, and C. Sirivichayakul, Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine, Am, J. Trop. Med. Hyg, issue.1, pp.7526-7554, 2006.

B. Guy, M. Saville, and J. Lang, Développement d'un vaccin tétravalent contre la dengue, Virologie, vol.14, issue.5, pp.311-332, 2010.

B. Guy, F. Guirakhoo, V. Barban, S. Higgs, M. T. Lang et al., Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses, Vaccine, vol.28, issue.3, pp.28632-649, 2010.
DOI : 10.1016/j.vaccine.2009.09.098

F. Guirakhoo, J. Arroyo, and K. V. Pugachev, Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine, Journal of Virology, vol.75, issue.16, pp.757290-7304, 2001.
DOI : 10.1128/JVI.75.16.7290-7304.2001

R. Galler, R. Marchevsky, and E. Caride, Attenuation and immunegeni-city of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys, Braz J Med Biol Res, issue.12, pp.381835-381881, 2005.

M. Appaiahgari and S. Vrati, : a Yellow fever virus-based novel Japanese encephalitis vaccine, Expert Review of Vaccines, vol.9, issue.12, pp.1371-84, 2010.
DOI : 10.1586/erv.10.139

R. Men, M. Bray, D. Clark, C. R. Lai, and C. , Dengue Type 4 Virus Mutants Containing Deletions in the 3' Non-coding Region of the RNA Genome: Analysis of Growth Restriction in Cell Culture and Altered Viremia Pattern and Immunogenicity in Rhesus Monkeys, J Virol, issue.6, pp.703930-3937, 1996.

J. Blaney, . Jr, A. Durbin, B. Murphy, and S. Whitehead, Development of a Live Attenuated Dengue Virus Vaccine Using Reverse Genetics, Viral Immunology, vol.19, issue.1, pp.10-32, 2006.
DOI : 10.1089/vim.2006.19.10

A. P. Durbin, K. R. Sun, and W. , Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'- untranslated region, Am, J. Trop. Med. Hyg, issue.5, pp.65-405, 2001.

J. M. Troyer, K. A. Hanley, and S. S. Whitehead, A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes, Am, J. Trop. Med. Hyg, issue.5, pp.65414-419, 2001.

S. S. Whitehead, B. Falgout, K. A. Hanley, J. E. Blaney-jr, L. Markoff et al., A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys, Journal of Virology, vol.77, issue.2, pp.771653-1657, 2003.
DOI : 10.1128/JVI.77.2.1653-1657.2003

J. E. Blaney-jr, H. C. Hanley, K. A. , M. B. Whitehead, and S. S. , Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2, BMC Infectious Diseases, vol.77, issue.2, p.39, 2004.
DOI : 10.1128/JVI.77.7.3929-3938.2003

J. E. Blaney-jr, H. C. Firestone, C. Hanley, K. A. , M. B. Whitehead et al., Genetically modified, live attenuated dengue virus type 3 vaccine candidates, Am. J

S. Whitehead, K. Hanley, J. Blaney, . Jr, L. Gilmore et al., Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys, Vaccine, vol.21, issue.27-30, pp.27-304307, 2003.
DOI : 10.1016/S0264-410X(03)00488-2

A. Durbin, S. Whitehead, and J. Mcarthur, rDEN4??30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers, The Journal of Infectious Diseases, vol.191, issue.5, pp.710-718, 2005.
DOI : 10.1086/427780

A. Durbin, J. Mcarthur, and J. Marron, The Live Attenuated Dengue Serotype 1

A. Durbin, J. Mcarthur, and J. Marron, rDEN2/4??30(ME), a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Na??ve Adults, Human Vaccines, vol.2, issue.6, pp.255-260, 2006.
DOI : 10.4161/hv.2.6.3494

J. Blaney, . Jr, J. Matro, M. B. Whitehead, and S. S. Recombinant, Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys, Journal of Virology, vol.79, issue.9, pp.795516-5528, 2005.
DOI : 10.1128/JVI.79.9.5516-5528.2005

J. Blaney, . Jr, N. Sathe, and L. Goddard, Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3??? untranslated region (3???-UTR) or by exchange of the DENV-3 3???-UTR with that of DENV-4, Vaccine, vol.26, issue.6, pp.26817-828, 2008.
DOI : 10.1016/j.vaccine.2007.11.082

J. Mcarthur, A. Durbin, and J. Marron, Phase I Clinical Evaluation of rDEN430- 200,201: A Live Attenuated Dengue 4 Vaccine Candidate Designed for Decreased Hepatotoxicity, Am J Trop Med Hyg, issue.5, pp.79678-684, 2008.

P. Wrigth, A. Durbin, and S. Whitehead, Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN430-4995 in healthy adult volunteers, Am J Trop Med Hyg, issue.5, pp.81834-841, 2009.

J. E. Blaney-jr, N. Sathe, C. Hanson, C. Firestone, M. B. Whitehead et al., Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN430 with those of DEN1, Virol J, issue.4, p.23, 2007.

D. Widman, I. Frolov, and P. Mason, Third-Generation Flavivirus Vaccines Based on Single-Cycle, Encapsidation-Defective Viruses, Adv Virus Res, pp.77-126, 2008.

C. Huang, S. Butrapet, and D. Pierro, Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine, Journal of Virology, vol.74, issue.7, pp.743020-743028, 2000.
DOI : 10.1128/JVI.74.7.3020-3028.2000

S. Butrapet, J. Rabablert, and S. Angsubhakorn, Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys, Southeast Asian J Trop Med Public Health, vol.33, issue.3, pp.589-99, 2002.

C. Huang, S. Butrapet, and K. Tsuchiya, Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development, Journal of Virology, vol.77, issue.21, pp.7711436-7711483, 2003.
DOI : 10.1128/JVI.77.21.11436-11447.2003

C. Huang, S. Silengo, M. Whiteman, and R. Kinney, Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate, p.53

J. Putnak, B. Coller, and G. Voss, An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model, Vaccine, issue.35, pp.234442-4452, 2005.

R. Maves, C. Ore, R. Porter, K. Kochel, and T. , Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice, Clinical and Vaccine Immunology, vol.17, issue.2, pp.304-306, 2010.
DOI : 10.1128/CVI.00353-09

D. Clements, B. Coller, and M. Lieberman, Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys, Vaccine, vol.28, issue.15, pp.282705-2715, 2010.
DOI : 10.1016/j.vaccine.2010.01.022

C. Leng, S. Liu, and J. Tsai, A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity, Microbes and Infection, vol.11, issue.2, pp.288-295, 2009.
DOI : 10.1016/j.micinf.2008.12.004

L. Gil, C. Lopez, and L. Lazo, Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice, International Immunology, vol.21, issue.10, pp.1175-1183, 2009.
DOI : 10.1093/intimm/dxp082

S. Khanam, P. Rajendra, N. Khanna, and S. Swaminathan, An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes, BMC Biotechnol, issue.10, p.7, 2007.

D. Holman, D. Wang, and K. Raviprakash, Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes, Clinical and Vaccine Immunology, vol.14, issue.2, pp.182-189, 2007.
DOI : 10.1128/CVI.00330-06

K. Raviprakash, D. Wang, and D. Ewing, A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus, Journal of Virology, vol.82, issue.14, pp.826927-6934, 2008.
DOI : 10.1128/JVI.02724-07

S. Brandler, M. Lucas-houran, and A. Moris, Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus, PLoS Neglected Tropical Diseases, vol.61, issue.3, 2007.
DOI : 10.1371/journal.pntd.0000096.s002

URL : https://hal.archives-ouvertes.fr/pasteur-00285763

S. Brandler, C. Ruffie, and V. Najburg, Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses, Vaccine, vol.28, issue.41, pp.286730-6739, 2010.
DOI : 10.1016/j.vaccine.2010.07.073

URL : https://hal.archives-ouvertes.fr/pasteur-00530065

S. Murrell, S. Wu, and M. Butler, Review of dengue virus and the development of a vaccine, Biotechnology Advances, vol.29, issue.2, pp.239-286, 2011.
DOI : 10.1016/j.biotechadv.2010.11.008

M. Pérez-vélez, T. García-nieves, C. Colón-sánchez, and I. Martínez, Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines, P R Health Sci J, issue.3, pp.28239-50, 2009.

P. Blair, T. Kochel, and K. Raviprakash, Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys, Viral Immunol, vol.21, issue.2, pp.123-155, 2008.

D. Lima, S. De-paula, and R. França, A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection, Vaccine, vol.29, issue.4, pp.831-839, 2011.
DOI : 10.1016/j.vaccine.2010.10.078

R. Suzuki, E. Winkelmann, and P. Mason, Construction and Characterization of a Single-Cycle Chimeric Flavivirus Vaccine Candidate That Protects Mice against Lethal Challenge with Dengue Virus Type 2, Journal of Virology, vol.83, issue.4, pp.1870-1880, 2009.
DOI : 10.1128/JVI.01891-08

A. Shustov and I. Frolov, Efficient, trans-complementing packaging systems for chimeric, pseudoinfectious dengue 2/yellow fever viruses, Virology, vol.400, issue.1, pp.8-17, 2010.
DOI : 10.1016/j.virol.2009.12.015

M. Simmons, T. Simmons, J. Lynch, and R. Putnak, Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy, Virology, vol.396, issue.2, pp.280-288, 2010.
DOI : 10.1016/j.virol.2009.10.023

G. Letson, P. Singhasivanon, and E. Fernandez, Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas, Human Vaccines, vol.144, issue.10, pp.6802-809, 2010.
DOI : 10.1098/rstb.1999.0428